TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence

✍ Scribed by Eveline Glynne-Jones; Maureen E. Harper; Liam T. Seery; Rhianedd James; Ian Anglin; Helen E. Morgan; Kathryn M. Taylor; Julia M. Gee; Robert I. Nicholson

• Book ID: 102270098
• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: French
• Weight: 258 KB
• Volume: 94
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.1450

✦ Synopsis

TENB2 encodes a putative transmembrane proteoglycan, related to the EGF/heregulin family of growth factors and follistatin, which has been identified through the application of a differential display technique to a xenograft model of prostate cancer. Northern analysis and competitive PCR were used to demonstrate significantly increased TENB2 expression (p ‫؍‬ 0.0003) on the acquisition of androgen independence in the model system. TENB2 is also overexpressed in clinical prostate carcinoma vs. its benign counterpart (p < 0.0001), with particular prominence in high-grade tumours, and shows a high degree of tissue specificity, being detected on a multitissue Northern array exclusively in brain and prostate material. Studies of recombinant protein expression demonstrate that TENB2 is a chondroitin sulphate proteoglycan. The presence of an EGF and 2 follistatin domains suggests a role in the regulation of growth factor signalling either as a ligand precursor, a membrane-bound receptor or as a binding protein for growth factors. These data are indicative of a significant role for TENB2 in the progression of poorly differentiated tumour types, with implications for prostate cancer detection, prognosis and therapy.